Innovative therapeutics

Investors

Press Releases

 
Press Releases
  Date Title View
Aug 24, 2016
SAN RAFAEL, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most Innovative Companies." This is the third consecutive year that BioMarin has received the recognition, acknowledging the company...
Aug 9, 2016
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to BioMarin from this offering are expected to be approximately $...
Aug 8, 2016
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwriters a 30-day option to purchase an additional 750,000 shares o...
Aug 4, 2016
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $340 to $360 million...
Jul 27, 2016
Potential First Treatment for Fatal, Rare, Brain Disease in ChildrenFDA Grants Priority Review Status and Breakthrough Therapy DesignationPDUFA Action Date is January 27, 2017MAA Submitted to European Regulatory AuthoritiesSAN RAFAEL, Calif., July 27, 2016 ...
Jul 27, 2016
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10% No Clinically Relevant Sustained Rises in ALT Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval Filing Conference Call and Web-cast with Slides to be...
Jul 21, 2016
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia will be presented at the XXXII International Congress of the World Federation of Hemophilia.  BM...
Jul 18, 2016
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of two biopharmaceutical veterans to its Board of Directors: Willard Dere, M.D., Professor of Internal Medicine at the University of U...
Jul 14, 2016
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 4, at 4:30 p.m. ET to discuss second quarter 2016 financial results and pr...
Jun 20, 2016
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia.  The presentation will report interim results of an open-la...
Page:
1
... NextLast
= add release to Briefcase
img_bottom-content

Diseases

MPS I, MPS VI, PKU, LEMS, Lysosomal Storage Disorders, Morquio A/MPS IVA

Products

VIMIZIM™, Kuvan®, Naglazyme®, Aldurazyme®, Firdapse®

Patient/Physician Contact Information

BioMarin Patient and Physician Support (BPPS)
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: bpps@bmrn.com

Top